Denosumab is an antiresorptive agent that significantly reduces bone turnover markers, increases mineral density and as a result, decreases the risk of vertebral fractures. The drug holiday effect on denosumab is associated with a high risk of multiple vertebrae fractures soon after the withdrawal. Discontinuation reasons may vary, but common reasons are the patient's will, discontinuation due to an upcoming dental procedure and long treatment period. Treatment of these fractures can be either surgical augmentation or conservative with the use of antiresorptive drugs. The purpose of this scientific paper is to review current data on the effect of either kyphoplasty or vertebroplasty on these types of fractures. Several studies showed that surgical augmentation is associated with a higher risk of multiple vertebrae fractures in comparison with conservative treatment and thus, it is not recommended, though more research is needed.

the soft tissue damage around the fracture 1,[4][5][6][7] .Segmental fractures of long bones have a significant impact on various aspects of the patient's life. In some cases the fracture does not allow the patient to work and has financial consequences. Trauma limits the patient's normal social life and functionality. The burden of long bone fractures affects society through the loss of productivity, the direct and indirect costs of treatment, and the additional contribution to morbidity and mortality. The management and treatment of segmental fractures of long bones burdens health systems significantly due to